Literature DB >> 6840828

Aggregation, chemotaxis, and chemiluminescence of canine granulocytes. Studies utilizing improved cell preparation techniques.

H Redl, P J Flynn, H Lamche, A Schiesser, G Schlag, D E Hammerschmidt.   

Abstract

Wishing to extrapolate in vitro observations of granulocyte function and pharmacology made with human cells to animal models of diseases in which we believe granulocyte stimulation to play a major role, we examined techniques for preparation of canine granulocytes and conducted a survey of the function and pharmacology of those cells. Isotonic density gradients of Percoll proved a simple and highly satisfactory method of preparation. Canine granulocytes in most respects paralleled human cells in function and pharmacology, except that canine cells lacked receptors for formylated oligopeptides and resisted them as stimuli; canine plasma contained a heat-labile inhibitor of canine PMN aggregation, oxidative metabolism, and myeloperoxidase release; canine PMNs were not inhibited in aggregation by protease inhibitors such as aprotinin; canine response to ibuprofen and steroids was more variable than that of human cells, and synergy between those agents was less readily demonstrated; heterologous stimulation (canine cells by human C5a or vice versa) led to a different time course and maximum response from those observed in the homologous systems. Canine granulocytes were readily marked with indium-111, and functioned normally in vitro and survived well in vivo after marking. We conclude that the dog is a suitable animal for studying the role of stimulated PMNs in disease, as long as the observed differences are taken into account in experimental design and data interpretation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6840828     DOI: 10.1007/bf00918009

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  27 in total

1.  Phagocytic activation of a luminol-dependent chemiluminescence in rabbit alveolar and peritoneal macrophages.

Authors:  R C Allen; L D Loose
Journal:  Biochem Biophys Res Commun       Date:  1976-03-08       Impact factor: 3.575

2.  Quantitative aspects of the production of superoxide radicals by phagocytizing human granulocytes.

Authors:  R S Weening; R Wever; D Roos
Journal:  J Lab Clin Med       Date:  1975-02

3.  Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage.

Authors:  T Sacks; C F Moldow; P R Craddock; T K Bowers; H S Jacob
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

Review 4.  Complement-induced granulocyte aggregation: an unsuspected mechanism of disease.

Authors:  H S Jacob; P R Craddock; D E Hammerschmidt; C F Moldow
Journal:  N Engl J Med       Date:  1980-04-03       Impact factor: 91.245

5.  Role of complement activation in a model of adult respiratory distress syndrome.

Authors:  S Hosea; E Brown; C Hammer; M Frank
Journal:  J Clin Invest       Date:  1980-08       Impact factor: 14.808

6.  Studies of the kinetics of indium-111-labeled granulocytes.

Authors:  B J Weiblen; L Forstrom; J McCullough
Journal:  J Lab Clin Med       Date:  1979-08

7.  Imaging experimental myocardial infarction with indium-111-labeled autologous leukocytes: effects of infarct age and residual regional myocardial blood flow.

Authors:  M L Thakur; A Gottschalk; B L Zaret
Journal:  Circulation       Date:  1979-08       Impact factor: 29.690

8.  Temporal factors in the reduction of myocardial infarct volume by methylprednisolone.

Authors:  C H Shatney; D J MacCarter; R C Lillehei
Journal:  Surgery       Date:  1976-07       Impact factor: 3.982

9.  Corticosteroids inhibit complement-induced granulocyte aggregation. A possible mechanism for their efficacy in shock states.

Authors:  D E Hammerschmidt; J G White; P R Craddock; H S Jacob
Journal:  J Clin Invest       Date:  1979-04       Impact factor: 14.808

10.  Zymosan-induced resistance to endotoxin and hemorrhagic shock.

Authors:  L D Joyce; J M Smith; H G Mauer; M Ameli; R C Lillehei
Journal:  Adv Shock Res       Date:  1978
View more
  14 in total

Review 1.  Rous-Whipple award lecture. The formylpeptide receptor of the neutrophil. A search and conserve operation.

Authors:  E L Becker
Journal:  Am J Pathol       Date:  1987-10       Impact factor: 4.307

2.  Chemiluminescence and chemotaxis assay of canine granulocytes: a methodological study.

Authors:  G Trowald-Wigh; K Thorén-Tolling
Journal:  Acta Vet Scand       Date:  1990       Impact factor: 1.695

3.  Feline polymorphonuclear leukocytes respond chemotactically to leukotriene B4 and activated serum but not to F-Met-Leu-Phe.

Authors:  G D Gray; G M Ohlmann; D R Morton; R G Schaub
Journal:  Agents Actions       Date:  1986-06

4.  Migration of dog polymorphonuclear neutrophilic leukocytes to formylated peptides.

Authors:  D Linnekin; C A Bowles; G Murano; T J MacVittie
Journal:  Inflammation       Date:  1990-12       Impact factor: 4.092

5.  Effect of a leukotriene B4 receptor antagonist on leukotriene B4-induced neutrophil chemotaxis in cavine dermis.

Authors:  D J Fretland; D L Widomski; J M Zemaitis; S W Djurić; R L Shone
Journal:  Inflammation       Date:  1989-10       Impact factor: 4.092

6.  In vitro effects of leukotriene B4 (LTB4) on canine PMN effector function(s).

Authors:  D F Gruber; M M D'Alesandro; T L Walden
Journal:  Agents Actions       Date:  1989-11

Review 7.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

8.  Leukotriene B4-induced granulocyte trafficking in guinea pig dermis. Effect of second-generation leukotriene B4 receptor antagonists, SC-50605 and SC-51146.

Authors:  D J Fretland; D L Widomski; C P Anglin; T D Penning; S Yu; S W Djuric
Journal:  Inflammation       Date:  1993-06       Impact factor: 4.092

9.  Pharmacological activity of the second generation leukotriene B4 receptor antagonist, SC-53228: effects on acute colonic inflammation and hepatic function in rodents.

Authors:  D J Fretland; C P Anglin; D Widomski; D A Baron; T Maziasz; P F Smith
Journal:  Inflammation       Date:  1995-10       Impact factor: 4.092

10.  Molecular analysis of the bovine anaphylatoxin C5a receptor.

Authors:  Sailasree Nemali; Daniel W Siemsen; Laura K Nelson; Peggy L Bunger; Craig L Faulkner; Pascal Rainard; Katherine A Gauss; Mark A Jutila; Mark T Quinn
Journal:  J Leukoc Biol       Date:  2008-05-14       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.